Loading…
← CockpitCompetitor Analysis › CAPR Capricor Therapeutics, Inc.Open in the cockpit ↗

Capricor Therapeutics, Inc.CAPRCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum neutral 42
Mkt cap
$467M
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$37.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-124.7 pp
WACC 8.5%
Hurdle
n/a
no reverse DCF
Next earnings
113 days
11 Mar 2027
Close · USD$8.03
1D-4.5%
1W-28.4%
1M+21.5%
3M+17.5%
6M-70.2%
YTD-72.2%
1Y+43.4%
ATR %12.5%
Beta1.41
52w lowhigh80.1% off high

What Capricor Therapeutics does

Employees: 231

Capricor Therapeutics at a glance

Size Capricor Therapeutics (CAPR) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $467M, the 2722nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.03 on 18 Nov 2026.

Performance Over six months the shares fell 70.2%, against -8.2% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 20 in its peer set.

Growth Revenue fell 100.0% over the last twelve months (peer median +13.0%).

Capital Return on invested capital runs 124.7 points below its cost of capital (8.5% WACC).

Short interest Short interest is 32.3% of the free float (30 Oct 2026).

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Relative performance

5010021 May 202621 Aug 202618 Nov 2026Peer median 94CAPR 28
Six months, rebased to 100: Capricor Therapeutics against the median of its 20 peers (local-currency closes).

Capricor Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$22.3M$25.2M$2.55M
Revenue growth—-100%-12%+887%—
Gross profit-$2.56M-$1.89M$20.8M$24.1M$1.86M
EBITDA-$151M-$106M-$41.1M-$23.0M-$29.0M
Net income-$148M-$105M-$40.5M-$22.3M-$29.0M
Free cash flow-$146M-$81.5M-$41.5M-$27.6M$1.56M
Capital expenditure$26.3M$11.7M$1.54M$2.05M$3.36M
Total debt$92.2M$17.9M$4.83M$5.61M$5.94M

Quarterly statements and history in the cockpit →

Capricor Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%KPL002370EOLS66200026933012013705AQSTASMBSMSPHARMAHNSARGNX688373GUFICBIO003020300584CAPR6-month return →1-month return →
Up and to the right = strong over both horizons. Capricor Therapeutics is the large dot.

Capricor Therapeutics competitors and peer comparison

How Capricor Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Capricor Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureCAPRPeer medianRank in peer set
1-month return+21.5%-3.2%3rd highest of 21
6-month return-70.2%-8.2%lowest of 20
Distance from 52-week high-80.1%-36.0%lowest of 21
Revenue growth (TTM)-100.0%+13.0%lowest of 20
ROIC minus cost of capital-124.7 pp-3.3 pplowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Capricor Therapeutics CAPRUnited States$467M-70%-100%n/an/an/an/a
Kwality Pharmaceuticals KPL.NSIndia$467M+110%+48%22%7.2×n/an/a
Zhejiang Yatai Pharmaceutical 002370.SZChina$468M-32%-4%-11%8.8×n/an/a
Evolus EOLSUnited States$468M+7%+14%-5%1.8×n/an/a
Handa Pharmaceuticals 6620.TWOTaiwan$469M+45%-16%30%16.6×24.8%+126.7%
Hainan Shuangcheng Pharmaceuticals 002693.SZChina$465M-28%+40%13%10.8×44.1%+1.0%
BlossomHill Therapeutics BLSMUnited States$464Mn/an/an/an/an/an/a
ChengDa PharmaCeuticals 301201.SZChina$472M-47%+27%-9%4.8×n/an/a
YungShin Global 3705.TWTaiwan$472M+5%-5%15%2.0×-3.8%+0.7%
Aquestive Therapeutics AQSTUnited States$475M-9%+13%-114%10.9×n/an/a
Assembly Biosciences ASMBUnited States$458M-15%+80%-32%2.2×n/an/a
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%4.9×n/an/a
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%6.4×n/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%14.9×-4.7%+105.3%
REGENXBIO RGNXUnited States$480M+22%-5%-120%3.1×n/an/a
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%19.0×n/an/a
Gufic Biosciences GUFICBIO.NSIndia$452M+48%+17%14%4.3×n/an/a
Pulike Biological Engineering 603566.SSChina$449M-21%-9%5%2.4×4.5%+3.3%
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%2.0×n/an/a
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%4.3×3.3%-1.1%
Dong-A Socio 000640.KSSouth Korea$447M-8%+11%7%0.7×-6.6%+12.8%

Questions

Which companies are Capricor Therapeutics's closest peers?
The cockpit's peer set: Kwality Pharmaceuticals (KPL.NS), Zhejiang Yatai Pharmaceutical (002370.SZ), Evolus (EOLS), Handa Pharmaceuticals (6620.TWO), Hainan Shuangcheng Pharmaceuticals (002693.SZ), BlossomHill Therapeutics (BLSM), ChengDa PharmaCeuticals (301201.SZ), YungShin Global (3705.TW).
How has Capricor Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -70.2% against -8.2% for the median peer; over one year +43.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.